SS-31 (Elamipretide): What the Research Shows

Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026

SS-31 is the research name of elamipretide, a synthetic four-amino-acid peptide that binds cardiolipin, a fat in the inner membrane of mitochondria (the cell’s energy producers); the FDA approved it in 2025 as Forzinity for Barth syndrome, a rare genetic disease, and it is promoted online for energy, endurance and anti-aging. Tested in people: the one randomized trial in Barth syndrome (12 patients) found no difference from placebo in walking distance or fatigue; reported in its open-label extension, knee strength rose in the 8 to 10 who continued, and the FDA granted an accelerated approval on that measure, with a confirmatory trial required. The evidence stops there: outside Barth syndrome every placebo-controlled trial of a clinical benefit missed its main goal or was small and early, the only study of an effect in people without a disease gave one infusion to 39 older adults, and no study in people of compounded or “research” SS-31 was found.

This review, part of our peptide library, keeps the approved product apart from what is sold as compounded or “research” SS-31. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.

At a glance

FDA status
Approved only as Forzinity, for Barth syndrome, under accelerated approval. Compounded or “research” SS-31 is not FDA-approved.
Evidence in people
Barth syndrome: the one randomized trial (12 people) missed both main goals. Larger trials in other diseases missed theirs.
The claim you’ve heard
Energy and anti-aging in healthy people: not tested, beyond one infusion in 39 older adults with no lasting change.
Doses tested in people
The label’s dose: 40 mg under the skin once daily. No injection trial measured an outcome below 4 mg.
Sport
Not established: WADA’s full Prohibited List was not searched for elamipretide for this review.

What SS-31 is

Elamipretide was developed by Stealth BioTherapeutics and is also called MTP-131 and Bendavia. Three things carry the name, and no result moves between them:

  • Forzinity, the approved product: elamipretide hydrochloride in a ready-to-use solution, injected under the skin.
  • Elamipretide as given in trials: the maker’s product, by injection under the skin, infusion into a vein, eye drops or, in two unreported phase 1 studies, by mouth. The pivotal Barth syndrome trials used a different salt, the acetate; the FDA’s review says “The to-be-marketed formulation containing elamipretide HCl was not assessed in the pivotal safety and efficacy clinical studies.” The FDA accepted the hydrochloride on a comparison of blood levels in healthy volunteers, which says nothing about any other maker’s product, or about compounding.
  • Compounded or “research” SS-31. No study in people of any such product was found, and no blood-level, purity or stability data.

Where it stands with the FDA

Status checked: November 19, 2026.

In plain words: elamipretide (SS-31) is FDA-approved in one form only, the injection Forzinity, for Barth syndrome, under an accelerated approval, with a confirmatory trial required. Compounded or “research” SS-31 is not FDA-approved; the salt in Forzinity, elamipretide hydrochloride, is in a group the FDA’s guidance calls eligible for use in compounding, federal law (section 503A) limits compounding copies of a marketed drug, and in a December 2025 letter to one supplier the FDA listed a different salt, the acetate, as ineligible.

As of November 19, 2026, elamipretide (SS-31) is FDA-approved only as Forzinity (elamipretide hydrochloride) injection, approved September 19, 2025 under accelerated approval and “indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”; its label says continued approval “may be contingent upon verification and description of clinical benefit in a confirmatory trial.” A product sold as compounded or “research” SS-31 is not FDA-approved, and the FDA’s August 2026 warning letters to four online sellers listed the SS-31 products they marketed for “research use only” among “unapproved new drugs”; elamipretide hydrochloride is a component of an approved drug, and the FDA’s guidance says such substances “are eligible for use in compounding under section 503A”, but section 503A limits compounding “regularly or in inordinate amounts” of “essentially copies of a commercially available drug product”. In a warning letter dated December 8, 2025, to a supplier of bulk ingredients, the FDA listed “elamipretide (SS-31) acetate” among active ingredients “that are ineligible for use in human drug compounding” under section 503A; the letter gives no reason for that ingredient and does not mention Forzinity. No FDA statement found for this review addresses compounding with elamipretide hydrochloride by name.

What the approval rests on. The label says the indication is approved “based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint”, and that in the randomized trial “FORZINITY was not superior to placebo on these primary endpoints.” The approval letter requires a trial “to verify and describe clinical benefit”, its final report due in March 2030, and says “we may withdraw this approval” if it “fails to verify clinical benefit”. Forzinity “is not approved for intravenous use”.

Compounded and “research” products. The FDA: “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” The four August 2026 letters concern each seller’s own products; none mentions Forzinity or compounding. We found no FDA letter about a pharmacy’s compounded elamipretide.

Other lists. Elamipretide is in none of the FDA’s compounding categories (as a component of an approved drug, elamipretide hydrochloride does not need one). HHS, the federal department the FDA belongs to, does not name it in its October 2026 draft interim policy.

Kansas. An injection is a sterile preparation, and Kansas’s rule (K.A.R. 68-13-4) says: “A pharmacist shall not compound a sterile preparation that is essentially a copy.” It adds: “Any pharmacist may compound a sterile preparation that is commercially available only if there is sufficient documentation of a specific medical need for the prescription or the product is temporarily unavailable due to problems other than safety or effectiveness.” We read nothing from either Kansas board about elamipretide.

Sport. Not established. The extracts of WADA’s 2026 and 2027 Prohibited Lists held for this library do not contain “elamipretide” or “SS-31”, but neither full List was searched for them, so this review states no class. WADA says a peptide it does not name “may still be prohibited”.

Claims you’ll see, and why sources disagree

Pages disagree for three reasons.

  • The approval is read as proof. A seller’s guide says the Barth trial “showed meaningful gains in strength and endurance, leading to FDA approval in 2025”; the randomized trial missed both primary endpoints.
  • The status is misstated, both ways. Pages read in November 2026 still said “Not FDA-approved.” or “Investigational in the United States.”; a page selling a “research” product said “It became FDA-approved in 2025 for Barth syndrome.”, true only of Forzinity. A directory says SS-31 “made from the acetate salt is outside 503A on FDA’s own statement”: wider than the FDA’s December 2025 letter, which went to one supplier and gives no reason.
  • Animal and lab findings are quoted as human ones. One page says SS-31 “Increases ATP synthesis by 30-50% in aged mitochondria”; no human source was found for any such percentage.

Where this review says “not tested in people”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.

Claim Level of evidence Verdict
“Mitochondrial repair”, more cellular energy Lab and animal studies; one measurement in people Not shown in people. One infusion raised a laboratory measure of muscle energy production in 39 older adults; no difference a week later.
Less fatigue; more endurance or strength Tested in people with two diseases Not shown: two placebo-controlled trials had fatigue and walking distance as primary endpoints and missed both. Knee strength rose only in the Barth extension, with no comparison group. Not tested in healthy people or athletes.
“anti-aging” Animal studies Mice only. No study in people has had an ageing outcome.
Heart benefits Tested in people Tested and not shown, in a heart-attack and a heart-failure trial; two more heart-failure trials were never reported.
“neuroprotection”, “Clearer thinking” Animal studies Not tested in people.
“No serious or dose-limiting side effects reported” Tested in people: the maker’s product only Not established. Forzinity’s label warns of “serious allergic reactions requiring emergency medical intervention”; no safety data were found for the products these pages sell.
Better combined with MOTS-c (a “stack”) No study found Not tested: no study of the combination with MOTS-c was found, in people or in animals.

What the evidence consists of

Stealth BioTherapeutics, the maker, funded or sponsored nearly every trial below. A primary endpoint is the main result a trial was designed to test.

Tested in people

Study People Design What happened Funding or limits
Barth syndrome (TAZPOWER, 2021) 12 Crossover against placebo, 12 weeks each Both primary endpoints missed: walk -0.8 m (95% CI -45.9 to 44.3), compatible with about 44 m of benefit or of harm; fatigue 0.1 (-0.8 to 0.9). Knee strength: 6.7 newtons (-24.8 to 38.2) Maker-funded; injection-site reactions may have revealed who got the drug (the FDA)
Mitochondrial myopathy (MMPOWER, 2018; MMPOWER-2, 2020; MMPOWER-3, 2023) 36; 30; 218 Five days of infusions; 4-week crossover; 24-week phase 3 Phase 3: both primary endpoints missed: walk -3.2 m (-18.7 to 12.3); fatigue -0.07 (-0.69 to 0.54; the abstract prints another interval). Infusions: 64.5 m against 20.4 m at the highest dose (p = 0.053). Crossover: 19.8 m (-2.8 to 42.5), endpoint missed; fatigue questionnaires favoured elamipretide at nominal significance, which phase 3 did not confirm Maker-funded. Phase 3 rules out an average gain above about 12 m; a post hoc subgroup (29 and 29) did better
Heart attack (EMBRACE STEMI, 2016) 300; about 118 in the primary analysis One infusion around angioplasty, against placebo Primary endpoint (infarct size) missed; imaging and clinical outcomes no better Maker-sponsored; abstract only
Heart failure (2017; PROGRESS-HF, 2020) 36; 71 One infusion; 28 days of injections, against placebo Injections: primary endpoint missed: difference in heart volume 2.3 mL (-1.9 to 6.5) at the higher dose, -0.3 (-4.6 to 4.0) at the lower; a small change either way is possible. Infusion: volumes fell briefly at the highest dose (8 people) Maker-sponsored; abstracts only
Eye (ReCLAIM-2, 2025; an optic-nerve trial, 2024) 176; 12 48 weeks of injections; 52 weeks of eye drops Primary endpoints missed in both; exploratory or post hoc measures favoured elamipretide (a retinal layer, “nominal P = 0.0034”; visual field) Maker-sponsored; a phase 3 trial (313 people) is running
Kidney-artery procedure (EVOLVE, 2017) 14 One infusion against placebo A scan marker of oxygen shortage favoured elamipretide; the registered primary outcome, filtration at 8 weeks, rose numerically more on placebo Part maker-funded; “pilot trial”; terminated
Older adults without disease (MOTION, 2021) 39, aged 60 to 85, enrolled for “poorly functioning mitochondria” One infusion against placebo Hand-muscle energy production higher right after (“P = 0.055”, “P = 0.045”); “No difference was found on day 7”; no significant effect on fatigue resistance (a post hoc count of contractions favoured the drug) Maker-funded; three authors were its paid consultants in 2014-2016

How the FDA read the Barth evidence. An advisory committee voted “Yes: 10 No: 6 Abstain: 0” on effectiveness. In May 2025 the FDA declined to approve; at resubmission its clinical and statistical staff found “not substantial evidence of effectiveness on knee muscle strength for accelerated approval”, and the signing official approved, accepting “more uncertainty than we would accept for more common diseases” in a “very rare (~150 subjects in the United States), serious disease with no approved treatments”. The review adds: “we cannot conclude at the present time that the observed increases in muscle strength in a single muscle group assessed using HHD provides clinical benefit” (HHD: a handheld strength meter).

Finished and never reported. NuPOWER, a phase 3 trial in mitochondrial disease (102 people, completed 2024; a company press release names it but gives no result); two heart-failure trials (46 and 308 people, completed 2017), the second the largest ever run with this drug.

Reported in people

None had a placebo group, so none can separate the drug from everything else.

  • Barth syndrome, open-label extension (10 entered; 8 completed 168 weeks). Knee strength: median 124 newtons at the start, median gain 34 at week 12 and 63 at week 168. The paper reports 96.1 m more walking at week 168; the FDA found gains “generally only 8-22 meters” in all but two. Two left for hives or a drug rash; one who stopped still gained strength.
  • Barth syndrome, comparison with 19 untreated registry patients (8 treated). Walking was 79.7 m and 91.0 m better in the paper; the FDA: “these findings do not establish a treatment effect of elamipretide”.
  • Case reports (children with Barth syndrome; two adults with other mitochondrial diseases). Ejection fraction rose from 20% to “60%” in a newborn and from 20% to 50% in a 5-year-old, alongside standard heart-failure treatment. The FDA: “These data are inconclusive with respect to clinical benefit”.
  • Other uncontrolled studies. Myopathy extension (28 people): walking down 54.0 m by the end. Macular degeneration phase 1 (21 and 19 people): dim-light vision “+5.6 letters” among 18 finishers and “+5.4 ± 7.9 letters” among 15.

Animal studies

  • Ageing mice. Weeks of treatment improved measures of muscle energy production, exercise tolerance and heart relaxation; one study found no significant change in “biological age” markers in most treated groups. No lifespan study was found. Four of the six ageing studies read here share authors; independent replication was not assessed.
  • Barth syndrome mice. The FDA: it “did not persuasively improve cardiac fractional shortening (a measure of function) or cardiac ventricular fibrosis”.
  • Toxicology. Rats (26 weeks) and dogs (39 weeks): “no significant systemic toxicities were observed”, with injection-site reactions “at all doses in both species”. No animal cancer study has been done; the FDA has required two.

Lab studies and how it is thought to work

The label says Forzinity “is a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function.” The FDA’s review rests that on “nonclinical studies”. Measured in people, it does not “meaningfully impact the elevated cardiolipin ratio” of Barth syndrome (the FDA). That binding cardiolipin produces a benefit a person can feel is theory, not yet shown.

Dosing: what has been tested, what is used, and what the reasoning supports

This section reports and reasons; it recommends nothing. The FDA’s review says the maker “did not conduct a dose ranging study in patients with Barth syndrome” and that “there are no adequate data to demonstrate an exposure response relationship”, so no dose can be called optimal.

Doses tested in people

All are the maker’s product; most doses by vein were set by body weight per hour of infusion.

Study or label People Dose Route How often and how long
Forzinity label Barth syndrome, 30 kg or more 40 mg; 20 mg for adults with severe kidney impairment Under the skin Once daily
Barth trial and extension 12 40 mg Under the skin Once daily; 12 weeks, then up to 192
Other trials under the skin Myopathy; heart failure; macular degeneration 40 mg; 4 mg in one heart-failure arm; 60 mg in NuPOWER (unreported) Under the skin Once daily; 4 to 160 weeks
Friedreich ataxia; case reports in children 20; a few 20-30 or 40-60 mg; 10 mg or 0.5 mg/kg a day, some first by vein at 0.25 to 0.5 mg/kg a day Under the skin; vein Once daily; 52 weeks; months
Infusion trials Myopathy; heart attack; heart failure; kidney; older adults 0.005 to 0.25 mg/kg per hour, for 1 to 4 hours; 20 mg in an unreported trial Vein Once, or daily for 5 to 7 days
Eye-drop studies Eye diseases 1% or 3% solution Eye drops Twice daily; 28 days to over 52 weeks
Phase 1: blood levels only Healthy volunteers 2 to 80 mg under the skin (60 or 80 mg five times in one day in two studies); infusions by vein; 10 to 100 mg by mouth (unreported) Under the skin; vein; mouth Up to 7 days

Every trial of injections or infusions lasting more than a day dosed once daily. No trial that measured a clinical outcome in adults used 1, 2, 5, 10 or 15 mg a day under the skin; whether the phase 1 studies did is not known. The longest exposure is 192 weeks, in three patients with Barth syndrome; without a disease, 7 days. No published study was found of dosing less often than daily, planned breaks (“cycles”), a step-up schedule or a combination with another peptide.

Doses in common use

These are amounts in circulation: practice that no trial set unless a bullet names a study, shown with where each comes from and how it compares with what was studied.

  • 5 to 10 mg a day under the skin, rising to 15 to 20 mg, for 8 to 12 weeks. The dominant figure on seller and aggregator pages; a telehealth clinic selling a compounded product states “Dose range: 5-10mg daily (standard); 15-20mg daily (advanced, under supervision).” No trial measured an outcome at these amounts under the skin in adults: they are one-eighth to one-half of the label’s 40 mg, which many of the same pages also give correctly.
  • About 1 to 5 mg a day, in cycles of 4 to 8 weeks with a break. Reported by forum summaries and newsletters. A telehealth seller’s own article says “0.5 to 2 mg/day SC is common but unsupported by controlled human efficacy data” (SC: under the skin). The one nearby dose tested for an effect, 4 mg in the heart-failure trial, did not differ from placebo.
  • Fewer than seven days a week. A telehealth seller of a compounded product states “5 mg” “Once daily, Monday to Friday”; others state “3–5 times per week” or “4 weeks on, 2 weeks off”. Every trial dosed daily and continuously.

What the pharmacology supports, and what it doesn’t

  • Amount (measured in people; then inferred). Blood levels rise in proportion to dose from 2 to 80 mg, so a few milligrams of the maker’s product would give a small fraction of the exposure at 40 mg.
  • Frequency (measured; then inferred). The half-life is about 3 to 4 hours, with no build-up on daily dosing; how long the drug stays in mitochondria is “not known” (the FDA). Nothing supports expecting an effect to last through days without a dose, but in mice twice-weekly treatment preserved some effects; in people it is untested.
  • Route (measured; then inferred). About 92% of a dose under the skin reaches the blood. By mouth, authors of an animal study call it “not orally bioavailable”; no human blood level after an oral dose is public.
  • Duration (measured; one claim not confirmed). In Barth syndrome 12 weeks showed nothing against placebo; to the maker’s argument that more time is needed, the FDA answered that “this hypothesis may not be supported by the data”. Breaks and cycles are convention.
  • Monitoring (from the label and the FDA’s review). Injection-site and allergic reactions; kidney function; eosinophil counts; and metformin, with which the FDA has required an interaction study.

Nobody knows whether any dose below 40 mg a day does anything, or what a milligram of any product other than the maker’s delivers.

What common protocols get wrong

  • The trial dose is misstated. A “research” seller’s guide calls 10 mg a day the “most common trial dose” (it was 40 mg); a newsletter says trial doses “went up to 40mg” (60 mg, and 80 mg in volunteers); an aggregator calls “20–40 mg” under the skin “matching clinical trial dosing for mitochondrial myopathy” (those trials gave 40 mg, and 60 mg in NuPOWER).
  • Trial lengths and the label are misstated. The same aggregator gives the Barth trial as “40 mg/day subcutaneously for 28 weeks” (drug was given for 12 of them) and says “No FDA-approved dosing guidelines exist for SS-31 outside of clinical trial protocols.” (a label exists); a telehealth seller’s table gives the macular-degeneration course as 24 weeks (ReCLAIM-2 ran 48).
  • Infusion figures appear on pages about injections. A telehealth seller cites “a range from 0.05mg/kg to 0.5mg/kg” with no route, and another page phase 1 doses “up to 0.25 mg/kg SC”. Both match intravenous doses; trial doses under the skin were fixed amounts.
  • Results are turned around. A newsletter credits the randomized trial with “a 96.1-meter improvement”: that is week 168 of the open-label extension. A seller lists “Reduced fatigue in clinical trials” for the phase 3 myopathy trial, which missed its fatigue endpoint. A directory credits “EMBRACE”, the heart-attack trial, with better walking in Barth syndrome.
  • Trials that can’t be found. Pages cite “SPARCLE”, “PIROUETTE” and a “Phase 3 SPARCL trial for heart failure”, none among the 34 registry records (one credits “SPARCLE” and EVOLVE with the heart-failure study’s infusion doses), call ReCLAIM-2 “Phase III” (it was phase 2) and call the heart-failure work a “NEJM-published trial” (it appeared elsewhere).
  • A mouse dose scaled to people. A community page’s amounts are “derived from rough allometric scaling of mouse anti-aging studies”: not a dose tested in people.

The dose is the prescriber’s decision for one patient.

Safety, and who should be most cautious

Everything known comes from the maker’s product in trials, mostly at 40 mg a day; none of it describes a compounded or “research” product. The FDA’s review finds “no notable safety concerns other than injection site reactions and hypersensitivity reactions”.

Injection-site reactions. In the Barth trial all 12 patients had one on elamipretide and 8 of 12 on placebo (redness 12 against 3; pain 9 against 5; hives 3 against none); in the phase 3 myopathy trial, 95.4% against 48.6%.

Allergy. People with a past serious allergic reaction to it have the most reason for caution: the label says they “should not be rechallenged”. It reports “serious allergic reactions requiring emergency medical intervention”, “within minutes to months after treatment initiation”. The FDA describes a woman treated by ambulance staff “as anaphylactic shock” 15 minutes after an injection (classed as a serious allergic reaction, not anaphylaxis) and a man with dermatitis about two months in.

The two larger placebo-controlled trials (macular degeneration, 117 against 59 people; myopathy, 109 against 109). Serious adverse events: 15.4% against 10.2%, and 4.6% against 2.8%; investigators judged none related to treatment. Stopped for an adverse event: 23.1% against 13.6%, and 7.3% against 2.8%. Deaths: 2 against none in the first (COVID-19; pneumonia), which the FDA judged “unlikely to be related to elamipretide”.

Eosinophils. These white blood cells rose in about half of treated patients (59 of 114 against 1 of 57; 55 of 109 against 3 of 108), peaked at about 90 days and returned to baseline, without symptoms.

Deaths in the heart-attack trial: the records disagree. ClinicalTrials.gov’s mortality row lists 10 of 150 on elamipretide and 3 of 147 on placebo, with no time frame; its participant-flow table gives death as the reason for not completing in 3 and 1; the EU register gives deaths from all causes as 3 and 3. Both list cardiogenic shock in 4 against none and serious events in 20 against 14. The abstract says “safe and well tolerated”; we could not read the full paper. The trial was not designed to compare deaths, and these records support no conclusion about them.

Other events. Barth extension: five serious events in three people, three “deemed unlikely to be related to elamipretide” and two in one participant months after his last dose. Suicidal ideation was recorded in two participants there, both with a history of it, and as one serious event on elamipretide (none on placebo) in the myopathy trial; the FDA drew no conclusion.

Theory. By the label’s reasoning, an overdose would look “histamine-related (e.g., decreased blood pressure, presyncope)” (near-fainting).

Situation What is known Basis
Pregnancy, breastfeeding No human data; no harm to offspring in rat and rabbit studies Label
Newborns; children under 30 kg Not approved for newborns: its preservative, benzyl alcohol, has caused fatal reactions in premature newborns. Not established under 30 kg Label
Severe kidney impairment Exposure 125% higher; the label halves the dose. Not studied on dialysis Label
Cancer, now or in the past No animal cancer study yet. Tumours were serious events in 2 of 117 on elamipretide, 3 of 59 on placebo, in one trial Label; the FDA

Product quality

  • The approved product. The FDA found the application “meets all applicable standards to support the identity, strength, quality, and purity that it purports”.
  • Products labelled “research use only”. Of that label the FDA wrote to one of the four sellers: “evidence obtained from your website establishes that your products are intended to be drugs for human use.” Each letter adds that injectable products “bypass some of the body’s key defenses against toxins and microorganisms”.
  • Laboratory analyses. No published analysis of SS-31 sold online, seized or compounded was found. A seller’s certificate of analysis is not evidence.

What we make of it

This section is our reading of the evidence. It is a judgment, not a finding.

For Barth syndrome, elamipretide is an approved medicine whose benefit is unconfirmed: the 12-person randomized trial showed no difference from placebo, the approval rests on one strength measure from an uncontrolled extension, the FDA’s own staff were split, and the trial meant to settle it reports in 2030.

Outside Barth syndrome, its use is unproven and experimental. A benefit where mitochondria are failing is plausible: it improved their function in animals and briefly raised a measure of muscle energy production in older adults. But the idea has been tested in people, and the answers so far are mostly no: the larger placebo-controlled trials missed their primary endpoints, and several finished trials were never reported.

The claims run ahead of that: energy, endurance and anti-aging in healthy people have not been tested, and what is sold online is neither the product nor the dose studied. The approval is not evidence for any of it.

What would have to be true: for Barth syndrome, a confirmatory trial that shows a benefit in function; for anything else, a placebo-controlled trial that meets its main goal; for other products, evidence of what they contain and deliver.

For whom elamipretide might ever be considered, after what, with what monitoring and when to stop are our Medical Director’s to state.

Peptide care at Rock Creek Wellness

Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.

So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.

What would change this review

  • The confirmatory trial in Barth syndrome (NCT07531251): placebo-controlled, an estimated 48 participants, 72 weeks; primary completion estimated for September 2029.
  • Results still to come: NuPOWER (NCT05162768); the phase 3 macular degeneration trial (NCT06373731); a four-week open-label study in adults aged 65 to 80 (NCT07275424).
  • Status: an FDA statement on compounding with elamipretide hydrochloride by name.

Common questions

Is SS-31 FDA-approved?

Only as Forzinity, for Barth syndrome, under an accelerated approval, with a confirmatory trial required. Compounded or “research” SS-31 is not FDA-approved.

Does SS-31 boost energy or slow aging in healthy people?

That has not been tested. In the one study of people without a disease, a single infusion in 39 older adults briefly raised a laboratory measure of muscle energy production. The anti-aging findings are from mice.

Is SS-31 safe?

For compounded or “research” SS-31, that is not established: no safety data were found. For Forzinity, the known reactions are injection-site reactions in nearly everyone and, less often, allergic reactions that have needed emergency care.

Can a doctor prescribe SS-31?

Forzinity is a prescription medicine, approved for Barth syndrome. A compounded medicine is made for one patient on a prescription and is not FDA-approved; federal law limits compounding of what is essentially a copy of a marketed drug, and Kansas has its own rule for sterile preparations.

How much SS-31 do people take, and how often?

The label’s dose, and the dose in most trials, is 40 mg under the skin once a day. Seller and aggregator pages state 5 to 10 mg a day, and forum summaries about 1 to 5 mg a day, often in cycles: practice that no trial set. The only such amount tested for an effect, 4 mg a day in a heart-failure trial, did not differ from placebo. The dose is the prescriber’s decision for one patient.

Sources

Show all 57 sourcesHide sources
  1. FORZINITY (elamipretide hydrochloride) injection, prescribing information and instructions for use, SPL version 11. Stealth Biotherapeutics Inc. / DailyMed (NLM), 2026.
  2. NDA 215244 Integrated Review, Forzinity (elamipretide). FDA CDER, 2025.
  3. NDA 215244 Other Action Letters (complete response letter, signed May 15, 2025). FDA CDER, 2025.
  4. NDA 215244 approval letter, Forzinity (elamipretide) injection. FDA CDER, 2025.
  5. Cardiovascular and Renal Drugs Advisory Committee, October 10, 2024: Final Summary Minutes. FDA, 2025.
  6. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA, 2025.
  7. 21 U.S.C. 353a (section 503A of the Federal Food, Drug, and Cosmetic Act). U.S. Code, read at Cornell Legal Information Institute, 2026.
  8. Compounding and the FDA: Questions and Answers. FDA, 2025.
  9. Warning letter: Darmerica, LLC, MARCS-CMS 716152. FDA, 2025.
  10. Peptide Partners LLC 735063 (warning letter, August 24, 2026). FDA, 2026.
  11. Peak Performance Peptides 735127 (warning letter, August 24, 2026). FDA, 2026.
  12. Royal Peptides LLC 734884 (warning letter, August 24, 2026). FDA, 2026.
  13. TXP Innovations LLC dba Tex Peptides 735067 (warning letter, August 24, 2026). FDA, 2026.
  14. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list). FDA, 2026.
  15. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
  16. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, 2026.
  17. K.A.R. 68-13-4, Sterile preparations. Kansas Secretary of State, 2018.
  18. Elamipretide, PubChem CID 11764719. NCBI, read 2026.
  19. NCT07531251 (the confirmatory trial in Barth syndrome). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  20. NCT05162768 (NuPOWER; no results posted). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  21. NCT02976038 (the mitochondrial myopathy extension). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  22. NCT01572909 (EMBRACE STEMI). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  23. NCT02814097 (heart failure with preserved ejection fraction; no results posted). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  24. NCT02914665 (hospitalized heart failure; no results posted). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  25. NCT01755858 (EVOLVE). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  26. NCT06373731 (ReNEW). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  27. NCT07275424 (the four-week study in adults aged 65 to 80). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  28. NCT05168774 (Friedreich ataxia). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  29. NCT01754818 (oral capsules, phase 1; no results posted). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  30. NCT01786915 (oral capsules, phase 1; no results posted). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  31. NCT02314299 (eye drops; no results posted). ClinicalTrials.gov, U.S. National Library of Medicine, read 2026.
  32. Clinical Trial Results: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia™ (MTP-131) on Reperfusion Injury in Patients Treated with Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction (EudraCT 2011-002824-42; sponsor protocol SPIRI-201; US NCT number NCT01572909). EU Clinical Trials Register (European Medicines Agency), 2020.
  33. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 2021.
  34. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine, 2024.
  35. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet Journal of Rare Diseases, 2022.
  36. Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases. JIMD Reports, 2023.
  37. Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. European Heart Journal Case Reports, 2025.
  38. Elamipretide in pediatric Barth syndrome: from heart failure to school return. Orphanet Journal of Rare Diseases, 2026.
  39. Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series. Clinical Case Reports, 2024.
  40. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 2018.
  41. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle, 2020.
  42. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology, 2023.
  43. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. European Heart Journal, 2016.
  44. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure, 2017.
  45. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure, 2020.
  46. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circulation: Cardiovascular Interventions, 2017.
  47. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One, 2021.
  48. Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study. Ophthalmology Science, 2022.
  49. Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study. Ophthalmology Science, 2022.
  50. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmology Science, 2025.
  51. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology, 2024.
  52. Stealth BioTherapeutics to Present Updates on Elamipretide in Barth Syndrome and POLG Disease at Euromit 2026 (press release, May 26, 2026). Stealth BioTherapeutics Inc., 2026.
  53. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine, 2019.
  54. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife, 2020.
  55. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell, 2025.
  56. Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. GeroScience, 2023.
  57. WADA 2026 Prohibited List; WADA 2027 Prohibited List; Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. World Anti-Doping Agency, 2025 and 2026.